Role of human epididymis protein 4 (HE4) as predictor of response to platinum based chemotherapy: a systematic

review of literature

Objective: Although epithelial ovarian cancer (EOC) treatment has greatly improved over the last three decades, a fraction of patients (40-60%) with advanced-stage disease fail to completely respond to standard therapy, because of chemo-resistance to platinum. For this reason, new predictive and monitoring tools were studied to identify platinum resistant EOC patients, with the purpose of improving and personalizing the treatment. In this review, we aim to discuss the latest evidence reported in the literature about the use of Human Epididymis 4 (HE4) to predict platinum resistance among EOC patients. Methods: A comprehensive search of the literature was conducted using the terms “HE4 epithelial ovarian cancer” and “human epididymis protein 4 epithelial ovarian cancer” and they were combined with the terms “chemotherapy”, “platinum” and “response”. Results: The search identified twelve papers, from January 1952 to December 2019, in line with eligibility criteria for this systematic review, all of which demonstrated good performance of HE4 in predicting platinum sensitivity or resistance. Conclusions: All the available studies present limited and non-homogeneous data, therefore more studies are needed to validate and reinforce the role of HE4 in predicting the response to platinum based chemotherapy among ovarian cancer patients.

Ovarian cancer; HE4; Chemotherapy; Platinum; Markers.

[1] Siegel R.L., Miller K.D., Jemal A.: “Cancer statistics, 2018”. CA. Cancer J. Clin., 2018, 68, 7-30.

[2] Agarwal R., Kaye S.B.: “Ovarian cancer: strategies for overcoming resistance to chemotherapy”. Nature Reviews Cancer, 2003, 3, 502-516.

[3] van Zyl B., Tang D., Bowden N.A.: “Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment”. Endocr. Relat. Cancer, 2018, 25, R303-R318.

[4] Armstrong D.K.: “Relapsed ovarian cancer: challenges and man-agement strategies for a chronic disease”. Oncologist, 2002, 7, 20-28.

[5] Stuart G.C.E., Kitchener H., Bacon M., duBois A., Friedlander M., Ledermann J., et al.: “2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the fourth ovarian cancer consensus conference”. Int. J. Gynecol. Cancer, 2011, 21, 750-755.

[6] Davis A., Tinker A.V., Friedlander M.: “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit ?” Gynecol. Oncol., 2014, 133, 624-631.

[7] Yang W., Lu Z., Bast R.C.: “The role of biomarkers in the management of epithelial ovarian cancer”. Expert Rev. Mol. Diagn., 2018, 17, 577-591.

[8] Ferraro S., Braga F., Lanzoni M., Boracchi P., Biganzoli E.M., Panteghini M.: “Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review”. J. Clin. Pathol., 2013, 66, 273-281.

[9] Teh B.H., Yong S.L., Sim W.W., Lau K.B., Suharjono H.N.: “Eval-uation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy”. Horm. Mol. Biol. Clin. Investig., 2018, 35, /j/hmbci.2018.35.issue-1/hmbci-2018-0029/hmbci-2018-0029.xml.

[10] Steffensen K.D., Waldstrøm M., Brandslund I., Petzold M., Jakobsen A.: “The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients”. Int. J. Gynecol. Cancer, 2012, 22, 1474-1482.

[11] Hamed E.O., Ahmed H., Sedeek O.B., Mohammed A.M., Abd-Alla A. A., Ghaffar H.M.A.: “Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response”. Diagn. Pathol., 2013, 8, 11.

[12] Angioli R., Capriglione S., Aloisi A., Guzzo F., Luvero D., Miranda A., et al.: “Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer ?” Tumor Biol., 2014, 35, 7009-7015.

[13] Chudecka-Głaz A., Cymbaluk-Płoska A., Menkiszak J., Sompolska-Rzechuła A., Tołoczko-Grabarek A., Rzepka-Górska I.: “Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer”. J. Ovarian Res., 2014, 7, 62.

[14] Aarenstrup Karlsen M., Høgdall C., Nedergaard L., Philipsen Prahm K., Schou Karlsen N.M., Weng Ekmann-Gade A., et al.: “HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer”. Apmis, 2016, 124, 1038-1045.

[15] Pelissier A., Roulot A., Guéry B., Bonneau C., Bellet D., Rouzier R.: “Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer”. J. Ovarian Res., 2016, 9, 61.

[16] Chudecka-Głaz A., Cymbaluk-Płoska A., Wężowska M., Menkiszak J.: “Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?” PLoS One, 2018, 13, e0194270.

[17] Moore R.G., Hill E.K., Horan T., Yano N., Kim K., MacLaughlan S., et al.: “HE4 (WFDC2) gene overexpression promotes ovarian tumor growth”. Sci. Rep., 2015, 4, 3574.

[18] Wang H., Zhu L., Gao J., Hu Z., Lin B.: “Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells”. Oncol. Rep., 2015, 33, 403-412.

[19] Zhu L., Gao J., Hu Z., Schwab C.L., Zhuang H., Tan M., et al.: “Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer”. Am. J. Cancer Res., 2015, 5, 830-843.

[20] Ribeiro J.R., Schorl C., Yano N., Romano N., Kim K.K., Singh R.K., et al.: “HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells”. J. Ovarian Res., 2016, 9, 28.

[21] Lee S., Choi S., Lee Y., Chung D., Hong S., Park N.: “Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer”. J. Obstet. Gynaecol. Res., 2017, 43, 220-227.

[22] Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M.: “Cancer Statistics, 2001”. CA. Cancer J. Clin., 2001, 51, 15-36.

[23] Cortez A.J., Tudrej P., Kujawa K.A., Lisowska K.M.: “Advances in ovarian cancer therapy”. Cancer Chemother. Pharmacol., 2018, 81, 17- 38.

[24] Johnson N., Liao J.B.: “Novel therapeutics for ovarian cancer”. Int. J. Gynecol. Cancer, 2017, 27, S14-S19.

[25] Plotti F., Capriglione S., Terranova C., Montera R., Aloisi A., Dami-ani P., et al.: “Does HE4 have a role as biomarker in the recurrence of ovarian cancer?” Tumor Biol., 2013, 33, 2117-2123.

[26] Scaletta G., Plotti F., Luvero D., Capriglione S., Montera R., Mi-randa A., et al.: “The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review”. Expert Rev. Anticancer Ther., 2017, 17, 827-839.

[27] Capriglione S., Luvero D., Plotti F., Terranova C., Montera R., Scaletta G., et al.: “Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature”. Med. Oncol., 2017, 34, 164.

[28] Innao P., Pothisuwan M., Pengsa P.: “Does human epididymis pro-tein 4 (HE4) have a role in prediction of recurrent epithelial ovarian cancer”. Asian Pac. J. Cancer Prev., 2017, 17, 4483-4486.

[29] Kaijser J., Van Belle V., Van Gorp T., Sayasneh A., Vergote I., Bourne T., et al.: “Prognostic value of serum HE4 levels and risk of ovarian malignancy algorithm scores at the time of ovarian cancer diagnosis”. Int. J. Gynecol. Cancer, 2014, 24, 1173-1180.

[30] Steffensen K.D., Waldstrøm M., Brandslund I., Lund B., Sørensen S. M., Petzold M., et al.: “Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer”. Oncol. Lett., 2019, 11, 3967-3974.